Arcus Biosciences Inc

NYSE: RCUS
$11.07
+$0.33 (+3.1%)
Closing Price on February 21, 2025

RCUS Stock Chart and Intraday Price

RCUS Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 3928 POINT EDEN WAY, HAYWARD, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,735.52M USD
Shares Outstanding 90,865,000
Arcus Biosciences is a pioneering biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. With a robust pipeline that includes treatments like Domvanalimab and AB308 for advanced cancers, and Etrumadenant for dual adenosine receptor antagonism, the company is at the forefront of clinical trials aimed at combating various malignancies. Additionally, Arcus is exploring treatments for inflammatory diseases in collaboration with industry leaders, demonstrating its commitment to advancing healthcare through groundbreaking research.

RCUS Articles

Biotechs Highlight 6 Stocks Insiders Are Buying Now
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a stake.
Trey Thoelcke
Published:

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published:

With Arcus Partnership vs. Buyout, Gilead Moves Beyond Remdesivir COVID-19 Focus
In a world where investors are starving to find growth, many of the well established biotech leaders and many of the large pharmaceutical companies have been acquiring growth on top of their own...
Jon C. Ogg
Published:
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.